Article Text

PDF

H pylori infection and reflux oesophagitis
  1. J Kountouras,
  2. C Zavos,
  3. D Chatzopoulos
  1. Department of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece
  1. Correspondence to:
    Dr J Kountouras
    8 Fanariou St, Byzantio, 551 33, Thessaloniki, Macedonia, Greece; jannismed.auth.gr

Statistics from Altmetric.com

We read with considerable interest the paper by Kuipers et al (Gut 2004;53:12–20) which found no significant adverse impact on the severity of reflux disease or its control after two years of omeprazole therapy following H pylori eradication, during which time gastritis largely healed. In the commentary by McColl (Gut 2004;53:5–7), it is stated that although published data are conflicting, Schwizer et al reported improvement in reflux symptoms following H pylori treatment.1 Our preliminary published data,2 which are in accordance with those of Schwizer and colleagues,1 consisted of a small cohort of 69 patients with gastro-oesophageal reflux disease (GORD) and irritable bowel syndrome (IBS). Forty patients were treated with omeprazole (20 mg/day) plus trimebutine (600 mg/day) for three months (group A) and 29 were treated with omeprazole (20 mg/day) as monotherapy for an equal period of time (group B). Inclusion and exclusion criteria matched those of Kuipers et al. Upper and lower gastrointestinal endoscopic, histological, and clinical evaluations were made at baseline. Furthermore, upper gastrointestinal evaluation was repeated three months post-treatment. At baseline, oesophagitis, confirmed by histology, and the histological presence of H pylori were observed in 67.5% and 62.1% and in 80% and 82.8% of groups A and B of patients, respectively. All H pylori positive patients received eradication treatment, as analysed in Kuipers et al’s paper. The eradication rate was observed in 84% of H pylori/positive patients in group A and in 83% of H pylori/positive patients in group B. Three months post-treatment, there was a significant improvement in GORD (p = 0.003), IBS symptoms (p<0.0001), and oesophagitis (p = 0.029) in group A compared with group B. At baseline, all 24 H pylori/positive patients who received omeprazole and the eradication regimen had GORD symptoms and 15 (62.5%) had histologically proven oesophagitis. Three months post-treatment, GORD was present in 12 (50%) patients (p<0.0001) and oesophagitis in nine (37.5%) (p>0.05). As improvement in oesophagitis did not reach a statistically significant level, our study was continued and results are shown in table 1 (unpublished data). All 45 H pylori/positive patients who received omeprazole and the eradication regimen had GORD and 29 (64.4%) had oesophagitis at baseline. Three months post-treatment, 22 (48.9%) had GORD symptoms (p<0.00001) and 18 (40%) had oesophagitis (p = 0.03) (Wilcoxon’s rank sum test, two tailed p values; data not shown in table 1). There was a statistically better response in patients who also received trimebutine.

In our preliminary study, Barrett’s oesophagus was observed in eight (20%) of 40 and in five (17.2%) of 29 patients in groups A and B, respectively, similar to that (24.3%) observed by Kuipers et al. As there is an increased prevalence of IBS in patients with GORD,3 it would be interesting to know how many of the patients in Kuipers et al’s study had symptoms suggestive of IBS, and if their regimen had results similar to ours.

Our data show that H pylori is frequent in GORD and may contribute to the pathogenesis of GORD by several mechanisms.2 Also, we propose that the increasing prevalence of GORD may be partially explained not just by the decrease in prevalence of H pylori infection, as suggested by McColl (Gut 2004;53:5–7), but rather by healing of H pylori associated peptic ulcer disease, which coexists with GORD.4,5 Thus eliminating peptic ulcer disease unmasks GORD.5

In our latest unpublished data, 18 (48.6%) of 37 patients, in whom H pylori was eradicated, had reflux symptoms on omeprazole compared with four (50%) of eight patients in whom H pylori was not eradicated. Although the latter group was too small to draw definite conclusions, it seems that eradicating H pylori did not make GORD more difficult to control. While the editorial advocates that H pylori eradication makes it more difficult to achieve long term control of GORD with omeprazole therapy, we suggest that H pylori eradication leads to better control of GORD symptoms and improves oesophagitis.

Table 1

Patient profile prior to and after the therapeutic regimens and comparisons between the two groups

References

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles